Chronic Inflammatory Demyelinating PolyneuropathyPhase 2NCT04480450
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
A Phase 2 study testing Rituximab in people with Chronic Inflammatory Demyelinating Polyneuropathy, run by University of Kansas Medical Center.
Trial summary
CIDP is a heterogeneous disease with variable responses to therapy. Recently, a distinctive subgroup of patients with serum autoantibodies to the paranodal proteins contactin and neurofascin have been identified. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Inflammatory Demyelinating Polyneuropathy
- What is being tested?
- Rituximab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Jul 2025to Sep 2025
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written informed consent obtained from subjects indicating that they understand the purpose of and procedures required for the study and are willing to participate
- Male or female, aged ≥18 years
- Documented diagnosis of typical CIDP according to the European Academy of Neurology/Peripheral Nerve Society criteria 202127
- Must be willing to complete the study and return for follow-up visits.
- Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months (1 year) after completion of treatment.
- Successfully treated CIDP patients. Data at or prior to the screening visit must show evidence that during the course of therapy either the INCAT score improved by 1 or more points or improvement occurred according to the physician opinion.
Show all 13Show fewer
- CIDP disease stability is based on 2 visits that are 3 or more months apart documented at or prior to the screening visit by assessing unchanged CIDP status per physician opinion. The subject must be at the same dosage and frequency of CIDP therapy in between these 2 timepoints.
- Belonging to 1 of the following 2 treatment groups:
- IVIg/SCIg for up to 3 years.
- IVIg/SCIg for more than 3 years.
- Off steroids for at least 3 months before screen visit. Topical steroids and infrequent intraarticular steroids are allowed.
- No anticipated change in dosage or CIDP therapy from week 0 to week 24.
- Off concurrent immunosuppressive agents (such as azathioprine, methotrexate, mycophenolate mofetil, or cyclosporine or cyclophosphamide or any other agent) for at least 6 months prior to screening visit.
Who cannot join
- Female subjects who are premenopausal and are
- pregnant on the basis of a serum pregnancy test,
- breast-feeding, or
- not using an effective method of double barrier (1 hormonal plus 1 barrier method or 2 simultaneous barrier methods) or birth control (birth control pills, male condom, female condom, intrauterine device, Norplant, tubal ligation, or other sterilization procedures).
- Participation in another clinical study within 30 days before entering the study or during the study
- Employee or direct relative of an employee of the study site or Sponsor
Show all 39Show fewer
- Other medical condition, laboratory finding, or physical exam finding that precludes participation
- A neuropathy of other causes, including:
- A motor syndrome that fulfils criteria for multifocal motor neuropathy (MMN) with conduction block
- CIDP with monoclonal gammopathy of uncertain significance (CIDP-MGUS) or monoclonal gammopathy associated with an oncologic diagnosis
- Neuropathies secondary to infections, disorders, or systemic diseases
- Drug-, biologic-, chemotherapy-, or toxin-induced peripheral neuropathy
- Hereditary demyelinating neuropathies
- Central demyelinating disorders (e.g. multiple sclerosis)
- Others, like polyneuropathy, lumbosacral radiculoplexus neuropathy
- Patients with known history prior to screening visit of nodal and paranodal (anti-NF155, anti- CNTN1, anti- Caspr1 or anti-NF140/186 antibody) performed at a laboratory meeting quality standards for cell-based assay method and if required other confirmatory assays
- Any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or may interfere with assessment of CIDP or outcome measures
- Cardiac insufficiency (New York Heart Association Classes III/IV), cardiomyopathy, significant cardiac arrhythmia requiring treatment, unstable or advanced ischemic heart disease, congestive heart failure or severe hypertension
- Subjects with current malignancy requiring chemotherapy and/or radiotherapy, or history of malignancy with less than 2 years of complete remission prior to screening. Exceptions are: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment
- Plasma exchange within the last 3 months of screen visit.
- Any prior treatment with a biologic (e.g. rituximab (MabThera®/Rituximab®), ocrelizumab (Ocrevus®), natalizumab (Tysabri®), alemtuzumab, TNF-α inhibitor)
- Abnormal laboratory parameters:
- creatinine >1.5 times the upper normal limit (UNL)
- hemoglobin (Hb) <10 g/dL
- absolute neutrophil count (ANC) <1000 cells/μl
- elevated liver enzymes (AST or ALT >2.5 x Upper Limit of Normal).
- platelets < 100,000/mL
- History of bone marrow hypoplasia, leucopenia, thrombocytopenia, significant anemia, clinical or laboratory evidence of immunodeficiency syndromes, that are not transient events or side effects related to a clinical procedure (i.e. plasmapheresis) and within one year of screening.
- Positive Hepatitis B or C serology (Hep B surface antigen and Hep C antibody). For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+], we will consult liver disease experts before starting and during treatment
- History of positive HIV (HIV conducted during screening if applicable)
- Receipt of a live vaccine within 4 weeks prior to randomization
- Contraindication to receiving rituximab
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
- History of recurrent significant infection or history of recurrent bacterial infections
- Known active bacterial, viral fungal mycobacterial, or other infection (including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening
- Lack of venous access
- History of drug, alcohol, or chemical abuse within 6 months prior to screening
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications
- Levels of IgG or IgM that are below 30% of the lower limit of normal.
About this study
Official title: Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study
CIDP is a heterogeneous disease with variable responses to therapy. Recently, a distinctive subgroup of patients with serum autoantibodies to the paranodal proteins contactin and neurofascin have been identified. Although they present with active and serious disease, multiple clinical reports suggest that these patients can be cured with a treatment that depletes B cells and presumably eliminates pathogenic autoantibodies. However, beyond that subgroup of CIDP patients, which CIDP patients might benefit from Rituximab and B cell depletion is unknown. This Phase II study will treat 3 homogenous groups of 16 CIDP patients each with Rituximab in order to determine if there are subgroups that can be taken off current medications and put into long-term remission. The results from this study will be used to design a future larger trial. Biomarkers including paranodal antibodies, serum neurofilament light chains, anti-ganglioside antibodies will be obtained in order to learn about disease pathogenesis and possibly target therapy
- Being tested
- Rituximab
- Keywords
- CIDP
- Medical subject headings
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RituximabDrug
Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a mouse human chimeric monoclonal antibody against CD20. Administration leads to between 90 and 100% peripheral B cell depletion via complement dependent cytotoxicity.
| Study group | Role | What they receive |
|---|---|---|
| IVIg/SCIg < 3 Years Arm | Active comparator | Patients with CIDP successfully treated with IVIg/SCIg for under 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2. Receives: Drug: Rituximab |
| IVIg/SCIg > 3 Years Arm | Active comparator | Patients with CIDP successfully treated with IVIg/SCIg for more than 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2. Receives: Drug: Rituximab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score
The INCAT disability scale captures upper and lower limb dysfunction separately on a scale of 0 to 5, which are then added together for a total composite score ranging between 0 and 10.15 Lower scores indicate no or minimal disability (no arm dysfunction or walking abnormality), and higher scores indicate more disability (no purposeful arm movement or restricted to wheelchair). The adjusted INCAT disability score is identical to the INCAT disability score with the exception that changes in upper limb function from 0 (normal) to 1 (minor symptoms) are excluded. This exclusion was made because upper limb changes from 0 to 1 (minor symptoms in the fingers which do not impair any functional activities) were not judged by regulatory agencies to be clinically significant in all patients. With the exception of a change in the upper limb score from 0 to 1, all other 1 point changes in the INCAT score are considered clinically significant.
Measured: 48 Weeks
Secondary outcomes (6)
Inflammatory-Rasch-built Overall Disability Scale (I-RODS)
The Rasch built overall disability scale for immune-mediated peripheral neuropathies (I-RODS) is a patient-based, linearly weighted scale that captures activity and social participation limitations in patients with CIDP.16 The assessment includes 24 questions that address upper and lower limb disability. These range in difficulty from ability to read a book, eat, or brush teeth to dance, stand for hours, and run. Participants are asked to indicate if they can easily perform the task, perform it with difficulty, or are unable to perform it at all. Both the ability of the patient and the perceived difficulty of a task are tallied for a raw R-ODS score that ranges between 0 (complete disability) and 48 (no disability). The resulting raw I-RODS score are then be transformed to a final I-RODS score ranging from 0 (severe disability) to 100 (no disability). A change in the I-RODS scores of ≥ 4 points (using the centile metric) is considered clinically meaningful.
Measured: 48 Weeks
Modified Fatigue Severity Scale (mFSS)
The fatigue severity scale (FSS) is one available tool to measure fatigue.17 FSS is a Rasch-built patient self-assessment questionnaire that measures fatigue severity and impact on activities and lifestyle by asking participants to respond to 7 separate items. Responses are scored on a 4-point scale (0= strongly disagree, 3 = strongly agree) with a total score range from 0 to 21. Higher scores indicate more fatigue.
Measured: 48 Weeks
Visual Analog Pain Severity Scale (VAS)
The pain VAS is a validated sensitive linear scale that has been widely used to assess pain in diverse populations of patients.18 The scale is comprised of a horizontal or vertical line, 10 centimeters in length, anchored by 2 verbal descriptors, one for each symptom extreme. A score of 0 indicates "no pain" while a score of 100 (100 mm scale) indicates "pain as bad as it could be" or "worst imaginable pain". The pain VAS is self-completed by the respondent by placing a line perpendicular to the VAS line at the point that represents their pain intensity. The score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. Higher scores indicate greater pain intensity
Measured: 48 Weeks
Martin vigorimeter grip strength
Grip strength provides a quantitative objective measure of grip strength and an instant measure of strength impairment. The Vigorimeter from Martin is a hand-held device that measures grip strength by recording the pressure generated from squeezing a rubber bulb. The rubber bulb is placed in the hand between the palm and the thumb and index fingers. Pressure expressed in Kilopascal is recorded with a nanometer. A result is obtained after the subject squeezes 3 times with each hand. The mean grip strength of three squeezes is recorded in each hand.
Measured: 48 Weeks
Medical Research Council (MRC) Sum Score
The MRC sum score is determined by assessing the following 8 muscle pairs: bilateral shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, index finger abduction, great toe dorsiflexion and foot dorsiflexion. The MRC sum score is a summation of the MRC grades (range 0 to 5 with 0 = paralysis; 1 = only a trace or flicker of muscle contraction is seen or felt; 2 = muscle movement is possible with gravity eliminated; 3 = muscle movement is possible against gravity; 4 = muscle strength is reduced, but movement against resistance is possible and 5 = normal strength given in full numbers. The MRC sum score ranges from 0 ("total paralysis") to 60 ("normal strength").
Measured: 48 Weeks
EuroQOL-5D
The EuroQOL-5D is a simple survey meant to assess quality of life in a wide range of health conditions.23 The measure has 2 parts. In the first part 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) are assessed by 1 of 5 levels of impairment: no problems, slight problems, moderate problems, severe problems, or extreme problems. The second part of the survey is a visual analogue scale assessing overall health on the day of assessment. The EuroQOL-5D has been extensively validated in numerous therapeutic areas and has been found to be sensitive, reliable, and have good internal consistency.
Measured: 48 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jul 2020
- Study startJul 2025 (estimated)
- Primary completionSep 2025 (estimated)
- Study completionSep 2025 (estimated)
Why it stopped: Unable to acquire funding
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Inflammatory Demyelinating PolyneuropathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Kansas Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mazen Dimachkie, MD, Principal investigator, University of Kansas Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04480450
- Sponsor's protocol ID
- R4CIDP
- Status last verified
- Sep 2025
- First submitted
- 16 Jul 2020
- Last updated
- 17 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study
- ClinicalTrials.gov ID
- NCT04480450
- Acronym / sponsor ID
- R4CIDP
- Keywords
- CIDP
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Unable to acquire funding
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of Kansas Medical CenterUniversity, hospital or other
- Study start
- Jul 2025 (estimated)
- Primary completion
- Sep 2025 (estimated)
- Study completion
- Sep 2025 (estimated)
- First posted
- 21 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CIDP is a heterogeneous disease with variable responses to therapy. Recently, a distinctive subgroup of patients with serum autoantibodies to the paranodal proteins contactin and neurofascin have been identified. Although they present with active and serious disease, multiple clinical reports suggest that these patients can be cured with a treatment that depletes B cells and presumably eliminates pathogenic autoantibodies. However, beyond that subgroup of CIDP patients, which CIDP patients might benefit from Rituximab and B cell depletion is unknown. This Phase II study will treat 3 homogenous groups of 16 CIDP patients each with Rituximab in order to determine if there are subgroups that can be taken off current medications and put into long-term remission. The results from this study will be used to design a future larger trial. Biomarkers including paranodal antibodies, serum neurofilament light chains, anti-ganglioside antibodies will be obtained in order to learn about disease pathogenesis and possibly target therapy
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| IVIg/SCIg < 3 Years Arm | Active comparator | Drug: RituximabPatients with CIDP successfully treated with IVIg/SCIg for under 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2. |
| IVIg/SCIg > 3 Years Arm | Active comparator | Drug: RituximabPatients with CIDP successfully treated with IVIg/SCIg for more than 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Written informed consent obtained from subjects indicating that they understand the purpose of and procedures required for the study and are willing to participate
- Male or female, aged ≥18 years
- Documented diagnosis of typical CIDP according to the European Academy of Neurology/Peripheral Nerve Society criteria 202127
- Must be willing to complete the study and return for follow-up visits.
- Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months (1 year) after completion of treatment.
Key exclusion criteria (39 listed)
- Female subjects who are premenopausal and are
- Participation in another clinical study within 30 days before entering the study or during the study
- Employee or direct relative of an employee of the study site or Sponsor
- Other medical condition, laboratory finding, or physical exam finding that precludes participation
- A neuropathy of other causes, including:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RituximabRituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a mouse human chimeric monoclonal antibody against CD20. Administration leads to between 90 and 100% peripheral B cell depletion via complement dependent cytotoxicity. | Drug | IVIg/SCIg < 3 Years Arm, IVIg/SCIg > 3 Years Arm |
Primary outcome
Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score
Time frame: 48 Weeks
The INCAT disability scale captures upper and lower limb dysfunction separately on a scale of 0 to 5, which are then added together for a total composite score ranging between 0 and 10.15 Lower scores indicate no or minimal disability (no arm dysfunction or walking abnormality), and higher scores indicate more disability (no purposeful arm movement or restricted to wheelchair). The adjusted INCAT disability score is identical to the INCAT disability score with the exception that changes in upper limb function from 0 (normal) to 1 (minor symptoms) are excluded. This exclusion was made because upper limb changes from 0 to 1 (minor symptoms in the fingers which do not impair any functional activities) were not judged by regulatory agencies to be clinically significant in all patients. With the exception of a change in the upper limb score from 0 to 1, all other 1 point changes in the INCAT score are considered clinically significant.
6 secondary outcomes
Inflammatory-Rasch-built Overall Disability Scale (I-RODS)
Time frame: 48 Weeks
Modified Fatigue Severity Scale (mFSS)
Time frame: 48 Weeks
Visual Analog Pain Severity Scale (VAS)
Time frame: 48 Weeks
Martin vigorimeter grip strength
Time frame: 48 Weeks
Medical Research Council (MRC) Sum Score
Time frame: 48 Weeks
EuroQOL-5D
Time frame: 48 Weeks
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Chronic Inflammatory Demyelinating Polyneuropathy
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Chronic Inflammatory Demyelinating Polyneuropathy
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
Enrolling by invitationPhase 3
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
Polyneuropathy, Inflammatory Demyelinating, Chronic
RecruitingPhase 1
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
B-cell Mediated Autoimmune Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mazen Dimachkie, MD principal investigator
University of Kansas Medical Center
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Rituximab in people with Chronic Inflammatory Demyelinating Polyneuropathy, run by University of Kansas Medical Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 39 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 17 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score (time frame: 48 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2025.